SRT2104

In preclinical studies, SRT2104 demonstrated a lowering of fasting blood glucose and insulin, reduced weight gain, increased energy expenditure, improved exercise tolerance and improved insulin sensitivity in the diet-induced obesity model of Type 2 Diabetes.

SRT2104 was Sirtris' first NCE to enter human trials. The Phase I program in healthy volunteers demonstrated favorable safety and tolerability. The Phase I program was followed by a small translational medicine study in acute inflammation as well as two clinical studies in Type 2 Diabetes. SRT2104 continues in separate Phase II trials in psoriasis and vascular disorders.

The data from the translational medicine study in the setting of acute inflammation with SRT2104 were presented at the 10^th World Congress on Inflammation in Paris, France in June 2011.

SRT2379

Our second NCE to enter human clinic trials is SRT2379, which is chemically and structurally distinct from resveratrol and SRT2104. In preclinical studies, SRT2379 demonstrated efficacy in multiple disease models of diabetes and inflammation. SRT2379 has recently completed Phase I clinical assessment for safety, tolerability and pharmacokinetics. In addition, SRT2379 has completed a small translational medicine study of acute inflammation in normal human volunteers.

SRT3025

Our third NCE, which has been shown to have broad pharmacological activity in animal models of metabolic, inflammatory and neurodegenerative disease. In June 2011, Phase I testing of SRT3025 in healthy volunteers was initiated to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following escalating single and repeat oral dosing. This trial has recently completed enrollment.